Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues

European Journal of Endocrinology

Volumn 168, Issue 1, 2013, Pages 9-13

  Oriola, Josep ^b   Lucas, Tomás ^f   Halperin, Irene ^b   Mora, Mireia ^b   Perales, Ma José ^b   Alvarez Escolá, Cristina ^g   De Miguel Novoa, Paz ^h   Soto, Gonzalo Díaz ^c   Salinas, Isabel ^a   Julián, María Teresa ^a   Olaizola, Izaskun ^a   Bernabeu, Ignacio ^d   Marazuela, Mónica ^e   Puig Domingo, Manuel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ARGININE; AROMATIC HYDROCARBON RECEPTOR; AROMATIC HYDROCARBON RECEPTOR INTERACTING PROTEIN 1; GENOMIC DNA; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AIP GENE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; EXON; FEMALE; GENE ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; GROWTH HORMONE SECRETING ADENOMA; HUMAN; INTRON; LEUKOCYTE; MALE; PREVALENCE; PRIORITY JOURNAL; SPAIN; TREATMENT RESPONSE; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ACROMEGALY; ADENOMA; ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; GERM-LINE MUTATION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; SOMATOSTATIN;

EID: 84871993516     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0457     Document Type: Article

References (18)

1. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 3189-3202. (doi:10.1172/JCI39375)
2. Melmed S. Pathogenesis of pituitary tumors. Nature Reviews. Endocrinology 2011 7 257-266. (doi:10.1038/nrendo.2011.40)
3. Ozawa A, Agarwal SK, Mateo CM, Burns AL, Rice TS, Kennedy PA, Quigley CM, Simonds WF, Weinstein LS, Chandrasekharappa SC et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. Journal of Clinical Endocrinology and Metabolism 2007 92 1948-1951. (doi:10.1210/jc.2006-2563)
4. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J & Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 2006 103 15558-15563. (doi:10.1073/pnas.0603877103)
5. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230. (doi:10.1126/science.1126100)
6. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T et al. Clinical characterization of familial isolated pituitary adenomas. Journal of ClinicalEndocrinology andMetabolism 2006 91 3316-3323. (doi:10.1210/jc.2005- 2671)
7. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, GuitelmanMA,MuratA, Emy P,Gimenez-RoqueploAP, TamburranoG et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 2007 92 1891-1896. (doi:10.1210/jc.2006-2513)
8. Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. PNAS 2007 104 4101-4105. (doi:10.1073/pnas.0700004104)
9. Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. Journal of Clinical Endocrinology and Metabolism 2010 95 E373-E383. (doi:10.1210/jc. 2009-2556)
10. Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2007 92 1952-1955. (doi:10.1210/jc.2006-2702)
11. Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P et al . Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology 2007 157 1-8. (doi:10.1530/EJE-07-0181)
12. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology 2011 165 509-515. (doi:10.1530/EJE-11-0304)
13. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 6290-6295. (doi:10.1210/jc.2005-0998)
14. Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I & Webb SM. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology and Metabolism 2010 95 4973-4978. (doi:10.1210/jc. 2010-0573)
15. Taboada GF, Luque RM, Neto LV, Machado EO, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 295-303. (doi:10.1530/EJE-07-0562)
16. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112-2118. (doi:10.1210/jc.2005-2110)
17. Occhi G, Trivellin G, Ceccato F, De Lazzari P, Giorgi G, Dematte S, Grimaldi F, Castello R, Davi MV, Arnaldi G et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. European Journal of Endocrinology 2010 163 369-376. (doi:10.1530/EJE-10-0327)
18. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T & Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clinical Endocrinology 2007 66 499-502. (Pubitemid 46434927)